Literature DB >> 11123056

Bone and joint complications related to Gaucher disease.

G M Pastores1, M J Patel, H Firooznia.   

Abstract

There is a broad spectrum of Gaucher disease-related skeletal complications, ranging from asymptomatic osteopenia to osteonecrosis (of the shoulders and hips) with secondary degenerative joint disease. Characterization of the pattern and severity of bone involvement in the individual patient requires the application of conventional and advanced radiographic techniques. The introduction of enzyme replacement therapy (ERT) for this inborn error of glycosphingolipid metabolism has focused great interest in determining the nature and extent of the bone responses with this mode of treatment. The multifactorial etiology of the bone complications necessitates a multifaceted approach, combining pharmacologic strategies with physical therapy and orthopedic intervention. As bone disease can lead to chronic pain and debility with a resultant adverse impact on quality of life, it is important that patients be monitored closely and that early intervention with ERT prior to established bone disease (infarction and fibrosis) be considered.

Entities:  

Mesh:

Year:  2000        PMID: 11123056     DOI: 10.1007/s11926-000-0059-x

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  28 in total

1.  The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study.

Authors:  A M Damiano; G M Pastores; J E Ware
Journal:  Qual Life Res       Date:  1998-07       Impact factor: 4.147

2.  Activator protein deficient Gaucher's disease. A second patient with the newly identified lipid storage disorder.

Authors:  H Christomanou; A Chabás; T Pámpols; A Guardiola
Journal:  Klin Wochenschr       Date:  1989-10-02

3.  Gaucher disease: assessment with MR imaging.

Authors:  A Lanir; H Hadar; I Cohen; Y Tal; J Benmair; R Schreiber; M E Clouse
Journal:  Radiology       Date:  1986-10       Impact factor: 11.105

4.  Malignant epithelioid hemangioendothelioma of the tibia associated with a bone infarct in a patient who had Gaucher disease. A case report.

Authors:  M R Pins; H J Mankin; R J Xavier; D I Rosenthal; G R Dickersin; A E Rosenberg
Journal:  J Bone Joint Surg Am       Date:  1995-05       Impact factor: 5.284

5.  Thrombophilia and hypofibrinolysis: pathophysiologies of osteonecrosis.

Authors:  C J Glueck; R Freiberg; T Tracy; D Stroop; P Wang
Journal:  Clin Orthop Relat Res       Date:  1997-01       Impact factor: 4.176

6.  Bone density in Type 1 Gaucher disease.

Authors:  G M Pastores; S Wallenstein; R J Desnick; M M Luckey
Journal:  J Bone Miner Res       Date:  1996-11       Impact factor: 6.741

7.  MR imaging in adults with Gaucher disease type I: evaluation of marrow involvement and disease activity.

Authors:  G Hermann; R S Shapiro; I F Abdelwahab; G Grabowski
Journal:  Skeletal Radiol       Date:  1993       Impact factor: 2.199

8.  Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease.

Authors:  L A Johnson; B E Hoppel; E L Gerard; S P Miller; S H Doppelt; G C Zirzow; D I Rosenthal; J M Dambrosia; S C Hill; R O Brady
Journal:  Radiology       Date:  1992-02       Impact factor: 11.105

9.  Skeletal complications of Gaucher disease.

Authors:  D W Stowens; S L Teitelbaum; A J Kahn; J A Barranger
Journal:  Medicine (Baltimore)       Date:  1985-09       Impact factor: 1.889

10.  Resolution of a proximal humeral defect in type-1 Gaucher disease by enzyme replacement therapy.

Authors:  G M Pastores; G Hermann; K Norton; R J Desnick
Journal:  Pediatr Radiol       Date:  1995
View more
  19 in total

Review 1.  Radiological aspects of Gaucher disease.

Authors:  Robert Katz; Tom Booth; Rikin Hargunani; Peter Wylie; Brian Holloway
Journal:  Skeletal Radiol       Date:  2010-07-25       Impact factor: 2.199

2.  Bone marrow involvement in Gaucher disease at MRI : what long-term evolution can we expect under enzyme replacement therapy?

Authors:  Benjamin Fedida; Sébastien Touraine; Jerôme Stirnemann; Nadia Belmatoug; Jean-Denis Laredo; David Petrover
Journal:  Eur Radiol       Date:  2015-04-16       Impact factor: 5.315

Review 3.  Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history.

Authors:  Hagit N Baris; Ian J Cohen; Pramod K Mistry
Journal:  Pediatr Endocrinol Rev       Date:  2014-09

4.  Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey.

Authors:  Marion M G Brands; Deniz Güngör; Johanna M P van den Hout; Francois P J Karstens; Esmee Oussoren; Iris Plug; Jaap Jan Boelens; Peter M van Hasselt; Carla E M Hollak; Margot F Mulder; Estela Rubio Gozalbo; Jan A Smeitink; G Peter A Smit; Frits A Wijburg; Hanka Meutgeert; Ans T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2014-07-22       Impact factor: 4.982

5.  Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients.

Authors:  A El-Beshlawy; L Ragab; I Youssry; K Yakout; H El-Kiki; K Eid; I M Mansour; S Abd El-Hamid; M Yang; P K Mistry
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

Review 6.  Mandibular and dental manifestations of Gaucher disease.

Authors:  H R Saranjam; E Sidransky; W Z Levine; A Zimran; D Elstein
Journal:  Oral Dis       Date:  2012-01-18       Impact factor: 3.511

Review 7.  Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring.

Authors:  Antonio Baldellou; Generoso Andria; Pauline E Campbell; Joel Charrow; Ian J Cohen; Gregory A Grabowski; Chris M Harris; Paige Kaplan; Kieran McHugh; Eugen Mengel; Ashok Vellodi
Journal:  Eur J Pediatr       Date:  2003-12-16       Impact factor: 3.183

Review 8.  Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.

Authors:  Olive Jung; Samarjit Patnaik; Juan Marugan; Ellen Sidransky; Wendy Westbroek
Journal:  Expert Rev Proteomics       Date:  2016-04-21       Impact factor: 3.940

Review 9.  Glucocerebrosidase is shaking up the synucleinopathies.

Authors:  Marina Siebert; Ellen Sidransky; Wendy Westbroek
Journal:  Brain       Date:  2014-02-14       Impact factor: 13.501

10.  Orthoester functionalized N-guanidino derivatives of 1,5-dideoxy-1,5-imino-d-xylitol as pH-responsive inhibitors of β-glucocerebrosidase.

Authors:  Alen Sevšek; Javier Sastre Toraño; Linda Quarles van Ufford; Ed E Moret; Roland J Pieters; Nathaniel I Martin
Journal:  Medchemcomm       Date:  2017-10-10       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.